简体中文 | ENGLISH
Your location:Home > Company > Development history

In 1965, Southwest Synthetic pharmaceutical factory was founded in Yubei District, Chongqing.
In 1987, Sulphamethazine, Trimethoprim and Sulfamethoxazole passed US FDA site inspection.
In 1990, Cuntan manufacturing base was constructed in Jiangbei District, Chongqing.
In 1993, changed the company name as Southwest Synthetic pharmaceutical Corp., Ltd.
In 1990, Cuntan manufacturing base was constructed in Jiangbei District, Chongqing.
In 1993, changed the company name as Southwest Synthetic pharmaceutical Corp., Ltd.
In 1996, Sulfadimidine and Sulfadiazine received COS/CEP.
In 1996, listed as key pharmaceutical enterprise of China.
In 1997, listed on Shenzhen Stock Exchange. (Stock code: 000788)
In 2003, acquired by Founder Group through capital increase investment.
Till 2004, all products have been GMP certified.
In 2008, listed as a brand leader export enterprise by Chongqing government..
In 2008, R&D center was qualified as a national-level technology center.
In 2009, Southwest Synthetic pharmaceutical Corp., Ltd became the holder of Chongqing Daxin Pharmaceutical Co., Ltd through directional add-issuance.
Till 2009, 12 products (including Daxin’s products) have been approved by US FDA, including Sulfadiazine, Sulfamethoxazole, Trimethoprim, Sulfamethazine, Sulfamethazine sodium, Nabumetone, Meclizine hydrochloride, Lovastatin, Mycophenolic acid, Tobramycin, Amikacin sulfate, Amikacin.
In 2010, the construction of PKU International HealtherCare Group Chongqing pharmaceutical manufacturing base in Chongiqng Liangjiang New Area commenced.
Till 2010, 7 products (including Daxin’s products) have been granted CEP, including Sulfadiazine, Sulfamethoxazole, Trimethoprim, Sulfadimidine, Hydrochlorothiazide, Tobramycin and Tobramycin form I.
In September 2011, Southwest Synthetic Pharmaceutical Corp., Ltd acquired Beijing Beiyi Pharmaceutical Co., Ltd. through directional add-issuance, in this way, Southwest Synthetic Pharmaceutical Corp., Ltd. expanded its business from pharmaceutical manufacturing to pharmaceutical circulation and built a national sales circulation platform.
In 2012, the phase I of Chongqing Pharmaceutical Manufacturing Base was completed for debugging and trail operation phase.
In 2012, we became one of the top 50 of Chinese Medicine Industry of brand competitiveness.
In 2012, our company was listed in the key enterprises of Improving New Industrialization of Chongqing.
In January2013, our home-grown anticancer innovative drug have been in phase II、III.
In November 2013, our company officially changed the name to PKU HealthCare Co., Ltd.

 

CopyRight © 2010 FSSPC.COM All Rights reserved.渝ICP备09003354号